Loading MindReaderBio...
PhD/MD Science + Investor Acumen
Bridging the gap between clinical data and market-beating returns by providing specialized research and strategic investment across listed biotech, general equities, and private equity.
Biotech investing requires a complete 360° view. We bridge the gap between science and finance.
Scientific Excellence
PhD/MD-Level Analysis
- Deep dive into Mode of action
- Trial design evaluation
- Statistical rigor check
- Competitive landscape
Investor Expertise
Proven Financial Success
- >90% portfolio returns 2025
- 36% average 2020-2026
- Risk-adjusted sizing
- Entry/exit strategies
Latest Insights
Expert analysis on biotech trends, clinical data, and market moves.
Investors Note
29 Apr 2026
FDA, Vinay Prasad, and the question of regulatory direction in biotech
Read Article →
Science Desk
22 Apr 2026
IMMUNOLOGY2026: The Field Is Moving Toward Precision Immunology
Read Article →
Science Desk
8 Apr 2026
What chemotherapy actually does and why a quiet revolution is replacing it
Read Article →
Science Desk
29 Apr 2026
Your Immune System Was Always the Answer. We Just Learned How to Ask.
mRNA cancer vaccines are not the future of oncology they are happening now. Here is exactly why this technology works, why it took a decade to get here, and why the next five years will rewrite how we treat cancer.
Read Article →
Science Desk
17 Mar 2026
Engineering the TIL Frontier: Building the Infrastructure for Next-Generation Cell Therapy
Read Article →
Food for Thought
5 Mar 2026
What Ails America
Read Article →
Science Desk
10 Jan 2026
How Cancer Vaccines Train the Body to Fight Tumors
Read Article →
Science Desk
26 Jan 2026
Why IL-15 Is Changing Cancer Immunotherapy: The Biology Behind ANKTIVA
Read Article →
Science Desk
29 Dec 2025
The Rise of Bispecific and Trispecific Antibodies in Oncology
Read Article →
Science Desk
25 Feb 2026
Understanding Patrick Soon-Shiong’s NANT Cancer Vaccine: A Systems-Level War Map for Cancer
Read Article →
Food for Thought
15 Dec 2025
Glycemic Index Fiber the new protein
Read Article →
Who This Is For
We are not for everyone. We build high-conviction portfolios for serious investors.
Ideal for Investors Who:
- Have experience investing but want biotech-specific expertise
- Understand that biotech is high-risk, high-reward
- Want to understand the SCIENCE behind the stocks
- Seek an edge beyond what CNBC or Bloomberg provides
- Value independent research (no Wall Street conflicts)
- Are willing to hold positions through volatility
NOT Suitable For:
- Day traders seeking quick flips
- Risk-averse investors (biotech is inherently volatile)
- Those expecting guaranteed returns
- Investors unwilling to do additional due diligence
- People looking for 'hot tips' without understanding the thesis
- Short-term thinking (weeks/months)
Performance Metrics
Results that
Outperform the Market.
>90%
Portfolio
Our 2025 integrated portfolio combining biotech and general equities, significantly outperformed the Nasdaq Composite and the S&P 500.
Win Rate
72%
Profitable Trades
Benchmark (XBI, NASDAQ BI, RUSELL 2000, DJIA, S & P 500)
15%
Estimated Market Avg
Total Transparency Commitment
We publish every recommendation, entry price, and exit in real-time. No hiding behind vague "watchlists".